CoChat

The Status of p53 Oligomeric and Aggregation States in Cancer

de Oliveira, Guilherme A. P., Petronilho, Elaine C., Pedrote, Murilo M., Marques, Mayra A., Vieira, Tuane C. R. G., Cino, Elio A., Silva, Jerson L. · 2020 · Biomolecules
Cited by 56

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Despite being referred to as the guardian of the genome, when impacted by mutations, p53 can lose its protective functions and become a renegade. The malignant transformation of p53 occurs on multiple levels, such as altered DNA binding properties, acquisition of novel cellular partners, or associating into different oligomeric states. The consequences of these transformations can be catastrophic. Ongoing studies have implicated different oligomeric p53 species as having a central role in cancer biology; however, the correlation between p53 oligomerization status and oncogenic activities in cancer progression remains an open conundrum. In this review, we summarize the roles of different p53 oligomeric states in cancer and discuss potential research directions for overcoming aberrant p53 function associated with them. We address how misfolding and prion-like amyloid aggregation of p53 seem to play a crucial role in cancer development. The misfolded and aggregated states of mutant p53 are prospective targets for the development of novel therapeutic strategies against tumoral diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom10040548

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 70

  1. Lane, 1979, T antigen is bound to a host protein in SV40-transformed cells, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
  2. Linzer, 1979, Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells, Cell, 17, 43, 10.1016/0092-8674(79)90293-9 · DOI · Paper page
  3. Rangel, 2015, Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer, Front. Oncol., 5, 97
  4. Costa, 2016, Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?, Cold Spring Harb. Perspect. Biol., 8, a023614, 10.1101/cshperspect.a023614 · DOI · Paper page
  5. Kastan, 1992, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell, 71, 587, 10.1016/0092-8674(92)90593-2 · DOI · Paper page
  6. Lowe, 1993, p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature, 362, 847, 10.1038/362847a0 · DOI · Paper page
  7. Halazonetis, 1993, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants, EMBO J., 12, 5057, 10.1002/j.1460-2075.1993.tb06199.x · DOI · Paper page
  8. Joerger, 2016, The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
  9. Saito, 2003, Phosphorylation site interdependence of human p53 post-translational modifications in response to stress, J. Biol. Chem., 278, 37536, 10.1074/jbc.M305135200 · DOI · Paper page
  10. Appella, 2001, Post-translational modifications and activation of p53 by genotoxic stresses, Eur. J. Biochem., 268, 2764, 10.1046/j.1432-1327.2001.02225.x · DOI · Paper page
  11. Sakamuro, 1997, The polyproline region of p53 is required to activate apoptosis but not growth arrest, Oncogene, 15, 887, 10.1038/sj.onc.1201263 · DOI · Paper page
  12. Gu, 1997, Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, Cell, 90, 595, 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
  13. Espinosa, 2001, Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment, Mol. Cell, 8, 57, 10.1016/S1097-2765(01)00283-0 · DOI · Paper page
  14. Leroy, 2014, TP53 mutations in human cancer: Database reassessment and prospects for the next decade, Hum. Mutat., 35, 672, 10.1002/humu.22552 · DOI · Paper page
  15. Taylor, 1996, p53 mutations in bladder tumors from arylamine-exposed workers, Cancer Res., 56, 294
  16. Sun, 1996, A novel p53 germline alteration identified in a late onset breast cancer kindred, Oncogene, 13, 407
  17. Silva, 2018, Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer, Acc. Chem. Res., 51, 181, 10.1021/acs.accounts.7b00473 · DOI · Paper page
  18. Milner, 1991, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, 65, 765, 10.1016/0092-8674(91)90384-B · DOI · Paper page
  19. Vaughan, 2012, p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity, Arch. Biochem. Biophys., 518, 79, 10.1016/j.abb.2011.12.006 · DOI · Paper page
  20. Will, 1998, Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing, Proc. Natl. Acad. Sci. USA, 95, 13681, 10.1073/pnas.95.23.13681 · DOI · Paper page
  21. Fontemaggi, 2011, ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters, OMICS, 15, 305, 10.1089/omi.2010.0084 · DOI · Paper page
  22. Liu, 2011, TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73, Mol. Cell Biol., 31, 4464, 10.1128/MCB.05574-11 · DOI · Paper page
  23. Girardini, 2011, A Pin1/mutant p53 axis promotes aggressiveness in breast cancer, Cancer Cell, 20, 79, 10.1016/j.ccr.2011.06.004 · DOI · Paper page
  24. Martynova, 2012, Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63, Oncotarget, 3, 132, 10.18632/oncotarget.447 · DOI · Paper page
  25. Song, 2007, p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat. Cell Biol., 9, 573, 10.1038/ncb1571 · DOI · Paper page
  26. Restle, 2008, Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants, Nucleic Acids Res., 36, 5362, 10.1093/nar/gkn503 · DOI · Paper page
  27. Rajagopalan, 2011, Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53, Nucleic Acids Res., 39, 2294, 10.1093/nar/gkq800 · DOI · Paper page
  28. Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
  29. Stenger, 1992, Formation of stable p53 homotetramers and multiples of tetramers, Mol. Carcinog., 5, 102, 10.1002/mc.2940050204 · DOI · Paper page
  30. Wang, 1995, Interaction of p53 with its consensus DNA-binding site, Mol. Cell Biol., 15, 2157, 10.1128/MCB.15.4.2157 · DOI · Paper page
  31. Stenger, 1994, p53 oligomerization and DNA looping are linked with transcriptional activation, EMBO J., 13, 6011, 10.1002/j.1460-2075.1994.tb06947.x · DOI · Paper page
  32. Okorokov, 2006, The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity, EMBO J., 25, 5191, 10.1038/sj.emboj.7601382 · DOI · Paper page
  33. Kearns, 2016, Two p53 tetramers bind one consensus DNA response element, Nucleic Acids Res., 44, 6185, 10.1093/nar/gkw215 · DOI
  34. Vyas, 2017, Diverse p53/DNA binding modes expand the repertoire of p53 response elements, Proc. Natl. Acad. Sci. USA, 114, 10624, 10.1073/pnas.1618005114 · DOI · Paper page
  35. Pedrote, 2020, Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers, iScience, 23, 100820, 10.1016/j.isci.2020.100820 · DOI · Paper page
  36. Gaglia, 2013, Activation and control of p53 tetramerization in individual living cells, Proc. Natl. Acad. Sci. USA, 110, 15497, 10.1073/pnas.1311126110 · DOI · Paper page
  37. Katz, 2018, Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers, Genes Dev., 32, 430, 10.1101/gad.304071.117 · DOI
  38. Rangel, 2012, Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer, J. Biol. Chem., 287, 28152, 10.1074/jbc.M112.340638 · DOI · Paper page
  39. Ghosh, 2017, p53 amyloid formation leading to its loss of function: Implications in cancer pathogenesis, Cell Death Differ., 24, 1784, 10.1038/cdd.2017.105 · DOI
  40. Clos, 2013, Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity, Biochem. Biophys. Res. Commun., 430, 963, 10.1016/j.bbrc.2012.11.130 · DOI
  41. Soteras, 2015, p53 protein aggregation promotes platinum resistance in ovarian cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
  42. Pedrote, 2019, Loss of the p53 transactivation domain results in high amyloid aggregation of the Delta40p53 isoform in endometrial carcinoma cells, J. Biol. Chem., 294, 9430, 10.1074/jbc.RA119.007566 · DOI · Paper page
  43. Ishimaru, 2003, Fibrillar aggregates of the tumor suppressor p53 core domain, Biochemistry, 42, 9022, 10.1021/bi034218k · DOI · Paper page
  44. Ishimaru, 2003, Conversion of Wild-type p53 Core Domain into a Conformation that Mimics a Hot-spot Mutant, J. Mol. Biol., 333, 443, 10.1016/j.jmb.2003.08.026 · DOI
  45. Levy, 2011, Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors, Int. J. Biochem. Cell Biol., 43, 60, 10.1016/j.biocel.2010.10.017 · DOI · Paper page
  46. Wang, 2013, Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase, Neurol. Sci., 34, 1421, 10.1007/s10072-012-1257-9 · DOI
  47. Klibanov, 2001, Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress, J. Cell Sci., 114, 1867, 10.1242/jcs.114.10.1867 · DOI · Paper page
  48. Latonen, 2019, Phase-to-Phase with Nucleoli—Stress Responses, Protein Aggregation and Novel Roles of RNA, Front. Cell Neurosci., 13, 151, 10.3389/fncel.2019.00151 · DOI · Paper page
  49. Audas, 2016, Adaptation to Stressors by Systemic Protein Amyloidogenesis, Dev. Cell, 39, 155, 10.1016/j.devcel.2016.09.002 · DOI · Paper page
  50. Silva, 2016, The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins, J. Biol. Chem., 291, 15482, 10.1074/jbc.R116.733428 · DOI · Paper page
  51. Kamagata, 2020, Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains, Sci. Rep., 10, 580, 10.1038/s41598-020-57521-w · DOI · Paper page
  52. Cordeiro, 2019, Modulation of p53 and prion protein aggregation by RNA, Biochim. Biophys. Acta Proteins Proteom., 1867, 933, 10.1016/j.bbapap.2019.02.006 · DOI
  53. Yang, D.S.S.A., Davtyan, A., Fathi, M., Safari, M.S., Klindziuk, A., Barton, M.C., Varadarajan, N., Kolomeisky, A.B., and Vekilov, P.G. (2020). Mesoscopic Liquid Clusters Represent a Distinct Condensate of Mutant p53. bioRxiv. · DOI
  54. Yoshida, 2004, Binding of RNA to p53 regulates its oligomerization and DNA-binding activity, Oncogene, 23, 4371, 10.1038/sj.onc.1207583 · DOI
  55. Kovachev, 2017, Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain, J. Biol. Chem., 292, 9345, 10.1074/jbc.M116.762096 · DOI · Paper page
  56. Safari, 2019, Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils, iScience, 12, 342, 10.1016/j.isci.2019.01.027 · DOI · Paper page
  57. Suwiwat, 2004, Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer, Clin. Cancer Res., 10, 2491, 10.1158/1078-0432.CCR-03-0146 · DOI · Paper page
  58. Gerotziafas, 2008, Clinical studies with anticoagulants to improve survival in cancer patients, Pathophysiol. Haemost. Thromb., 36, 204, 10.1159/000175158 · DOI
  59. Falanga, 2007, Heparin in tumor progression and metastatic dissemination, Semin. Thromb. Hemost., 33, 688, 10.1055/s-2007-991536 · doi:10.1055/s-2007-991536
  60. Alur, 2016, Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells, Gene, 585, 241, 10.1016/j.gene.2016.03.044 · DOI
  61. Hsu, H.K., Hsu, K.H., Cheng, Y.M., Suen, H.Y., and Peng, S.F. (2018). Development and In Vitro Evaluation of Linear PEI-Shelled Heparin/Berberine Nanoparticles in Human Osteosarcoma U-2 OS Cells. Molecules, 23. · DOI
  62. Karbownik, 2013, Hyaluronan: Towards novel anti-cancer therapeutics, Pharmacol. Rep., 65, 1056, 10.1016/S1734-1140(13)71465-8 · DOI
  63. Zhao, 2019, Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells, Oncogene, 38, 4297, 10.1038/s41388-019-0719-4 · DOI
  64. Pedrote, 2018, Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer, J. Biol. Chem., 293, 11374, 10.1074/jbc.RA118.003285 · DOI · Paper page
  65. Baud, 2018, Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines, Eur. J. Med. Chem., 152, 101, 10.1016/j.ejmech.2018.04.035 · DOI · Paper page
  66. Rangel, 2019, p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells, J. Biol. Chem., 294, 3670, 10.1074/jbc.RA118.004671 · DOI · Paper page
  67. Campos, 2018, Resveratrol prevents p53 aggregation in vitro and in breast cancer cells, Oncotarget, 9, 29112, 10.18632/oncotarget.25631 · DOI · Paper page
  68. Cino, 2016, Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds, Sci. Rep., 6, 32535, 10.1038/srep32535 · DOI · Paper page
  69. Chen, 2017, Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro, Biochem. Biophys. Res. Commun., 489, 130, 10.1016/j.bbrc.2017.05.111 · DOI
  70. Lima, 2020, Biophysical characterization of p53 core domain aggregates, Biochem. J., 477, 111, 10.1042/BCJ20190778 · DOI

Cited by

Metadata

Authors
de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L.
Venue
Biomolecules
Publisher
MDPI AG
Published
2020-04-04
Volume
10
Issue
4
Pages
548
ISSN
2218-273X
Cited by
56
References
15
Language
en
Funders
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (210008/2018)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (465395/2014-7)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.